Vaccine safety and immunogenicity signatures of human responses to VSV-ZEBOV – Sofia ref.: 115842

Informazioni relative al progetto

VSV-EBOVAC

ID dell’accordo di sovvenzione: 115842

DOI 10.3030/115842

Progetto chiuso

Data della firma CE 19 Marzo 2015

Data di avvio 1 Marzo 2015

Data di completamento 28 Febbraio 2019

Finanziato da

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Costo totale € 4 786 010,00

Contributo UE € 3 887 260,00

Coordinato da

SCLAVO VACCINES ASSOCIATION
Italy

Risultati finali

Documents, reports (5)

Distribution of intermediate samples (day 28) to partners involved in immunogenicity studies

Migration

Predictive correlates of protective immunity and safety determined.

Migration

Establishment of the External Advisory Board

Migration

Distribution of late samples (> day 28) to partners involved in immunogenicity studies

Migration

Distribution of early samples (day 0-14) to partners involved in immunogenicity studies

Migration

Websites, patent fillings, videos etc. (1)

Web site development and maintenance

Migration

Pubblicazioni

Peer reviewed articles (6)

Ebola vaccine R&D: Filling the knowledge gaps

Autori: Donata Medaglini, Ali M. Harandi, Tom H. M. Ottenhoff, Claire-Anne Siegrist, VSV-EBOVAC Consortium
Pubblicato in: Science Translational Medicine, Numero 7/317, 2015, Pagina/e 317ps24-317ps24, ISSN 1946-6234
Editore: American Association for the Advancement of Science
DOI: 10.1126/scitranslmed.aad3106

Immunomonitoring of human responses to the rVSV-ZEBOV Ebola vaccine

Autori: Donata Medaglini, Claire-Anne Siegrist
Pubblicato in: Current Opinion in Virology, Numero 23, 2017, Pagina/e 88-94, ISSN 1879-6257
Editore: Elsevier BV
DOI: 10.1016/j.coviro.2017.03.008

Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study

Autori: Angela Huttner, Selidji Todagbe Agnandji, Christophe Combescure, José F Fernandes, Emmanuel Bache Bache, Lumeka Kabwende, Francis Maina Ndungu, Jessica Brosnahan, Thomas P Monath, Barbara Lemaître, Stéphane Grillet, Miriam Botto, Olivier Engler, Jasmine Portmann, Denise Siegrist, Philip Bejon, Peter Silvera, Peter Kremsner, Claire-Anne Siegrist, Sanjeev KRISHNA, Marylyn M. ADDO, Stephan BECKER,
Pubblicato in: The Lancet Infectious Diseases, Numero 18/7, 2018, Pagina/e 738-748, ISSN 1473-3099
Editore: The Lancet Publishing Group
DOI: 10.1016/S1473-3099(18)30165-8

A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa

Autori: Angela Huttner, Christophe Combescure, Stéphane Grillet, Mariëlle C. Haks, Edwin Quinten, Christine Modoux, Selidji Todagbe Agnandji, Jessica Brosnahan, Julie-Anne Dayer, Ali M. Harandi, Laurent Kaiser, Donata Medaglini, Tom Monath, Pascale Roux-Lombard, Peter G. Kremsner, Tom H. M. Ottenhoff, Claire-Anne Siegrist
Pubblicato in: Science Translational Medicine, Numero 9/385, 2017, Pagina/e eaaj1701, ISSN 1946-6234
Editore: American Association for the Advancement of Science
DOI: 10.1126/scitranslmed.aaj1701

Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know?

Autori: Angela Huttner, Claire-Anne Siegrist
Pubblicato in: Expert Review of Vaccines, Numero 17/12, 2018, Pagina/e 1105-1110, ISSN 1476-0584
Editore: Future Drugs Ltd.
DOI: 10.1080/14760584.2018.1546582

Correlates of vaccine-induced protective immunity against Ebola virus disease

Autori: Donata Medaglini, Francesco Santoro, Claire-Anne Siegrist
Pubblicato in: Seminars in Immunology, Numero 39, 2018, Pagina/e 65-72, ISSN 1044-5323
Editore: Academic Press
DOI: 10.1016/j.smim.2018.07.003